Global HIV Therapy Market
Global HIV Therapy Market

HIV Therapy Comprehensive Study by Diagnosis (Antigen Tests, Antibody Tests, Nucleic Acid Tests (NATs)), Symptoms (Fever, Headache, Muscle Aches And Joint Pain, Rash) Players and Region - Global Market Outlook to 2027

HIV Therapy Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

May 2022 Edition 200 Pages 57 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is HIV Therapy?
HIV treatment entails taking highly effective antiretroviral therapy (ART) medications that work to control the virus. ART is recommended for all HIV patients, and people with HIV should begin ART as soon as possible after diagnosis, if possible on the same day. People on ART use an HIV treatment regimen, which is a combination of HIV medications. A person's initial HIV treatment regimen typically consists of three HIV medicines from at least two different HIV drug classes, all of which must be taken exactly as prescribed. There are several options that combine two or three different HIV medications into a single once-daily pill. Long-acting HIV injections, given every two months, are also available if a health care provider determines that user meet certain criteria.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledGlaxoSmithKline plc. (United Kingdom), Abbott (United States), ViiV Healthcare (Australia), Pfizer Inc. (United States), Sanofi (France), Gilead Sciences, Inc. (United States), Novartis AG (Switzerland) and Bristol-Myers Squibb Company (United States)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global HIV Therapy market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc. (United Kingdom), Abbott (United States), ViiV Healthcare (Australia), Pfizer Inc. (United States), Sanofi (France), Gilead Sciences, Inc. (United States), Novartis AG (Switzerland) and Bristol-Myers Squibb Company (United States) are some of the key players that are part of study coverage.

The market study is broken down and major geographies with country level break-up.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global HIV Therapy market by Type, Application and Region.

On the basis of geography, the market of HIV Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diagnosis, the sub-segment i.e. Antigen Tests will boost the HIV Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Fever will boost the HIV Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2021, the Food and Drug Administration (FDA) approved Cabenuva, which contains two different types of HIV drugs: cabotegravir and rilpivirine. take it as an injection once a month at the doctor’s office. It makes a much easier option for people who find it hard to remember to take their pills every day.


Market Trend
  • Strong R&D Initiatives From Key Companies Are All Driving HIV Therapy
  • Technology developments in sample processing of HIV

Market Drivers
  • The Rising Geriatric Population Worldwide
  • Growing Awareness Regarding Health Among Individuals

Opportunities
  • Rising Healthcare Expenditure
  • Government Favorable Incentives For HIV Treatment

Restraints
  • Side Effect Associated With HIV Treatment
  • Lack Of Awareness Regarding The Available Treatment Options

Challenges
  • Stringent Regulations, And Long Product Approval Process
  • Challenges To Develop HIV Therapy Products


Key Target Audience
HIV Therapy, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as GlaxoSmithKline plc. (United Kingdom), Abbott (United States), ViiV Healthcare (Australia), Pfizer Inc. (United States), Sanofi (France), Gilead Sciences, Inc. (United States), Novartis AG (Switzerland) and Bristol-Myers Squibb Company (United States) etc.

2. Can we have customized study for HIV Therapy Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Report Objectives / Segmentation Covered
By Diagnosis
  • Antigen Tests
  • Antibody Tests
  • Nucleic Acid Tests (NATs)

By Symptoms
  • Fever
  • Headache
  • Muscle Aches And Joint Pain
  • Rash

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Geriatric Population Worldwide
      • 3.2.2. Growing Awareness Regarding Health Among Individuals
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulations, And Long Product Approval Process
      • 3.3.2. Challenges To Develop HIV Therapy Products
    • 3.4. Market Trends
      • 3.4.1. Strong R&D Initiatives From Key Companies Are All Driving HIV Therapy
      • 3.4.2. Technology developments in sample processing of HIV
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global HIV Therapy, by Diagnosis, Symptoms and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global HIV Therapy (Value)
      • 5.2.1. Global HIV Therapy by: Diagnosis (Value)
        • 5.2.1.1. Antigen Tests
        • 5.2.1.2. Antibody Tests
        • 5.2.1.3. Nucleic Acid Tests (NATs)
      • 5.2.2. Global HIV Therapy by: Symptoms (Value)
        • 5.2.2.1. Fever
        • 5.2.2.2. Headache
        • 5.2.2.3. Muscle Aches And Joint Pain
        • 5.2.2.4. Rash
      • 5.2.3. Global HIV Therapy Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global HIV Therapy (Price)
  • 6. HIV Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ViiV Healthcare (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Gilead Sciences, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global HIV Therapy Sale, by Diagnosis, Symptoms and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global HIV Therapy (Value)
      • 7.2.1. Global HIV Therapy by: Diagnosis (Value)
        • 7.2.1.1. Antigen Tests
        • 7.2.1.2. Antibody Tests
        • 7.2.1.3. Nucleic Acid Tests (NATs)
      • 7.2.2. Global HIV Therapy by: Symptoms (Value)
        • 7.2.2.1. Fever
        • 7.2.2.2. Headache
        • 7.2.2.3. Muscle Aches And Joint Pain
        • 7.2.2.4. Rash
      • 7.2.3. Global HIV Therapy Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global HIV Therapy (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. HIV Therapy: by Diagnosis(USD Million)
  • Table 2. HIV Therapy Antigen Tests , by Region USD Million (2016-2021)
  • Table 3. HIV Therapy Antibody Tests , by Region USD Million (2016-2021)
  • Table 4. HIV Therapy Nucleic Acid Tests (NATs) , by Region USD Million (2016-2021)
  • Table 5. HIV Therapy: by Symptoms(USD Million)
  • Table 6. HIV Therapy Fever , by Region USD Million (2016-2021)
  • Table 7. HIV Therapy Headache , by Region USD Million (2016-2021)
  • Table 8. HIV Therapy Muscle Aches And Joint Pain , by Region USD Million (2016-2021)
  • Table 9. HIV Therapy Rash , by Region USD Million (2016-2021)
  • Table 10. South America HIV Therapy, by Country USD Million (2016-2021)
  • Table 11. South America HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 12. South America HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 13. Brazil HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 14. Brazil HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 15. Argentina HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 16. Argentina HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 17. Rest of South America HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 18. Rest of South America HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 19. Asia Pacific HIV Therapy, by Country USD Million (2016-2021)
  • Table 20. Asia Pacific HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 21. Asia Pacific HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 22. China HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 23. China HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 24. Japan HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 25. Japan HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 26. India HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 27. India HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 28. South Korea HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 29. South Korea HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 30. Australia HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 31. Australia HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 32. Rest of Asia-Pacific HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 33. Rest of Asia-Pacific HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 34. Europe HIV Therapy, by Country USD Million (2016-2021)
  • Table 35. Europe HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 36. Europe HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 37. Germany HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 38. Germany HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 39. France HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 40. France HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 41. Italy HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 42. Italy HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 43. United Kingdom HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 44. United Kingdom HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 45. Netherlands HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 46. Netherlands HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 47. Rest of Europe HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 48. Rest of Europe HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 49. MEA HIV Therapy, by Country USD Million (2016-2021)
  • Table 50. MEA HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 51. MEA HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 52. Middle East HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 53. Middle East HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 54. Africa HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 55. Africa HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 56. North America HIV Therapy, by Country USD Million (2016-2021)
  • Table 57. North America HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 58. North America HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 59. United States HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 60. United States HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 61. Canada HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 62. Canada HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 63. Mexico HIV Therapy, by Diagnosis USD Million (2016-2021)
  • Table 64. Mexico HIV Therapy, by Symptoms USD Million (2016-2021)
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. HIV Therapy: by Diagnosis(USD Million)
  • Table 74. HIV Therapy Antigen Tests , by Region USD Million (2022-2027)
  • Table 75. HIV Therapy Antibody Tests , by Region USD Million (2022-2027)
  • Table 76. HIV Therapy Nucleic Acid Tests (NATs) , by Region USD Million (2022-2027)
  • Table 77. HIV Therapy: by Symptoms(USD Million)
  • Table 78. HIV Therapy Fever , by Region USD Million (2022-2027)
  • Table 79. HIV Therapy Headache , by Region USD Million (2022-2027)
  • Table 80. HIV Therapy Muscle Aches And Joint Pain , by Region USD Million (2022-2027)
  • Table 81. HIV Therapy Rash , by Region USD Million (2022-2027)
  • Table 82. South America HIV Therapy, by Country USD Million (2022-2027)
  • Table 83. South America HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 84. South America HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 85. Brazil HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 86. Brazil HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 87. Argentina HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 88. Argentina HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 89. Rest of South America HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 90. Rest of South America HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 91. Asia Pacific HIV Therapy, by Country USD Million (2022-2027)
  • Table 92. Asia Pacific HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 93. Asia Pacific HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 94. China HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 95. China HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 96. Japan HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 97. Japan HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 98. India HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 99. India HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 100. South Korea HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 101. South Korea HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 102. Australia HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 103. Australia HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 104. Rest of Asia-Pacific HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 105. Rest of Asia-Pacific HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 106. Europe HIV Therapy, by Country USD Million (2022-2027)
  • Table 107. Europe HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 108. Europe HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 109. Germany HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 110. Germany HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 111. France HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 112. France HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 113. Italy HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 114. Italy HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 115. United Kingdom HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 116. United Kingdom HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 117. Netherlands HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 118. Netherlands HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 119. Rest of Europe HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 120. Rest of Europe HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 121. MEA HIV Therapy, by Country USD Million (2022-2027)
  • Table 122. MEA HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 123. MEA HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 124. Middle East HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 125. Middle East HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 126. Africa HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 127. Africa HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 128. North America HIV Therapy, by Country USD Million (2022-2027)
  • Table 129. North America HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 130. North America HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 131. United States HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 132. United States HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 133. Canada HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 134. Canada HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 135. Mexico HIV Therapy, by Diagnosis USD Million (2022-2027)
  • Table 136. Mexico HIV Therapy, by Symptoms USD Million (2022-2027)
  • Table 137. Research Programs/Design for This Report
  • Table 138. Key Data Information from Secondary Sources
  • Table 139. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global HIV Therapy: by Diagnosis USD Million (2016-2021)
  • Figure 5. Global HIV Therapy: by Symptoms USD Million (2016-2021)
  • Figure 6. South America HIV Therapy Share (%), by Country
  • Figure 7. Asia Pacific HIV Therapy Share (%), by Country
  • Figure 8. Europe HIV Therapy Share (%), by Country
  • Figure 9. MEA HIV Therapy Share (%), by Country
  • Figure 10. North America HIV Therapy Share (%), by Country
  • Figure 11. Global HIV Therapy share by Players 2021 (%)
  • Figure 12. Global HIV Therapy share by Players (Top 3) 2021(%)
  • Figure 13. Global HIV Therapy share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2021
  • Figure 17. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott (United States) Revenue: by Geography 2021
  • Figure 19. ViiV Healthcare (Australia) Revenue, Net Income and Gross profit
  • Figure 20. ViiV Healthcare (Australia) Revenue: by Geography 2021
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 23. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi (France) Revenue: by Geography 2021
  • Figure 25. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Gilead Sciences, Inc. (United States) Revenue: by Geography 2021
  • Figure 27. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 29. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 30. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2021
  • Figure 31. Global HIV Therapy: by Diagnosis USD Million (2022-2027)
  • Figure 32. Global HIV Therapy: by Symptoms USD Million (2022-2027)
  • Figure 33. South America HIV Therapy Share (%), by Country
  • Figure 34. Asia Pacific HIV Therapy Share (%), by Country
  • Figure 35. Europe HIV Therapy Share (%), by Country
  • Figure 36. MEA HIV Therapy Share (%), by Country
  • Figure 37. North America HIV Therapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline plc. (United Kingdom)
  • Abbott (United States)
  • ViiV Healthcare (Australia)
  • Pfizer Inc. (United States)
  • Sanofi (France)
  • Gilead Sciences, Inc. (United States)
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb Company (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation